{"id":"6157eba6-7d12-5e2b-a781-3f5377a39d5a","stable_key":"2921131d-0ba0-51d3-8f59-8c4be3b9ac08:cucurbitacin-formulation-exposure","predicate":"increases_tested_exposure_to","statement":"At equal oral formulation doses, nanosuspension increased measured peak concentration and exposure area for cucurbitacins B, D and E in rats.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"3fb46d2d-f411-50dd-8b2c-2407f70794b8","mechanism_event_label":"Changing the formulation changed exposure to each member.","subject":{"id":"513c5904-afa1-5469-8a27-08cc9574e93d","slug":"rat-cucurbitacin-nanosuspension","display_name":"Rat oral cucurbitacin nanosuspension formulation","entity_type_key":"cellular_process"},"object":{"id":"a544a561-7647-55f6-8ba1-c7ab0133f968","slug":"cucurbitacin-b","display_name":"Cucurbitacin B","entity_type_key":"small_molecule"},"evidence_count":1,"mechanism_event":{"id":"3fb46d2d-f411-50dd-8b2c-2407f70794b8","stable_key":"2921131d-0ba0-51d3-8f59-8c4be3b9ac08:cucurbitacin-formulation-exposure-event","event_type":"observed_relationship","label":"Changing the formulation changed exposure to each member.","description":"At equal oral formulation doses, nanosuspension increased measured peak concentration and exposure area for cucurbitacins B, D and E in rats.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"513c5904-afa1-5469-8a27-08cc9574e93d","slug":"rat-cucurbitacin-nanosuspension","display_name":"Rat oral cucurbitacin nanosuspension formulation","entity_type_key":"cellular_process"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"a544a561-7647-55f6-8ba1-c7ab0133f968","slug":"cucurbitacin-b","display_name":"Cucurbitacin B","entity_type_key":"small_molecule"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"13edf322-5d31-5a4e-802f-c7528fc2ef48","slug":"cucurbitacin-d","display_name":"Cucurbitacin D","entity_type_key":"small_molecule"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"d5631638-0ee3-537f-b7cc-cbd4958395d3","slug":"cucurbitacin-e","display_name":"Cucurbitacin E","entity_type_key":"small_molecule"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""}]},"contexts":[{"dimension":"availability_state","value_text":"biomarker_context","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null},{"dimension":"evidence_access","value_text":"Primary abstract","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"2025 rat pharmacokinetic formulation comparison; dose not specified in accessed abstract.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Does not establish human bioavailability or improved clinical safety.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Cucurbitacins collection; species, compartment, exposure, co-substrates and manipulation remain explicit.","comparator":null,"unit":null,"notes":"","entity":{"slug":"cucurbitacin","display_name":"Cucurbitacins","entity_type_key":"chemical_species"}},{"dimension":"plain_language","value_text":"Changing the formulation changed exposure to each member.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Comparison of the pharmacokinetic profiles of three triterpenoids after oral administration of a cucurbitacin tablet and nanosuspension by UHPLC-MS/MS. · 2025 · https://pubmed.ncbi.nlm.nih.gov/41001343/ · DOI 10.3389/fphar.2025.1647015","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"trigger_kind","value_text":"biomarker_context","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null}],"evidence":[{"id":"29a1958c-416c-5ce6-8576-623b352aaaa0","evidence_kind":"source_excerpt","locator":"Lines 388-394","start_line":388,"end_line":394,"excerpt":"## cucurbitacin-formulation-exposure\nChanging the formulation changed exposure to each member.\nAt equal oral formulation doses, nanosuspension increased measured peak concentration and exposure area for cucurbitacins B, D and E in rats.\nModel: 2025 rat pharmacokinetic formulation comparison; dose not specified in accessed abstract.\nLimitations: Does not establish human bioavailability or improved clinical safety.\nEvidence access: Primary abstract\nComparison of the pharmacokinetic profiles of three triterpenoids after oral administration of a cucurbitacin tablet and nanosuspension by UHPLC-MS/MS. · 2025 · https://pubmed.ncbi.nlm.nih.gov/41001343/ · DOI 10.3389/fphar.2025.1647015","model_system":"2025 rat pharmacokinetic formulation comparison; dose not specified in accessed abstract.","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Original curation paraphrase; evidence access and experimental limitations specified.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"77324310-00ce-5d28-9fc7-595fddae86b9","stable_key":"import-2921131d-0ba0-51d3-8f59-8c4be3b9ac08","title":"Cucurbitacins: thiol chemistry, cytoskeleton, metabolic dependencies and signaling (2026-09-20)","document_type":"imported_text","citation_label":"AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text.","file_path":"","sha256":"5c23ec61b9cf3d2966fb081d8617e1e1f7c522e86419b8ba2dcae09590121123","revision_id":"74251a06-3ba5-506c-b428-700eca0fb432","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}